Tesamorelin is a fully synthetic analogue of human growth hormone-releasing hormone (GHRH 1–44), a 44-residue peptide amide first characterised under the developmental code TH9507 (CAS 218949-48-5). What sets the molecule apart from native GHRH is a trans-3-hexenoyl group attached at the N-terminal tyrosine — this single acylation is the defining modification of the tesamorelin scaffold. This listing supplies the compound as a 20 mg lyophilised vial, a higher-strength format suited to laboratories running extended assay panels or requiring more material per reconstitution.
Across preclinical literature, tesamorelin has been examined as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs. Investigations have focused on how GHRHR engagement drives the cAMP/PKA cascade and elicits pulsatile, endogenous growth-hormone (GH) secretion, positioning the peptide as a reference probe for hypothalamic-pituitary-somatotropic axis studies. Research reported across endocrinology journals has also explored its behaviour in metabolic and adipose-tissue models.
The compound is described by the molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S, with an average molecular weight near 5,135.87 Da. Its N-terminal trans-3-hexenoic acid moiety is frequently cited in analytical contexts for the resistance it lends against dipeptidyl peptidase-4 (DPP-4) cleavage — a stability characteristic that matters when planning the longer research protocols for which the larger 20 mg fill is typically chosen.
Each 20 mg vial of Core Power Peptides tesamorelin is produced to a minimum purity of 99%+, confirmed by HPLC and mass spectrometry, and sealed after sterile lyophilisation. Batches are third-party tested and accompanied by a certificate of analysis on request.
Storage: Keep lyophilised tesamorelin at −20°C for long-term storage. After reconstitution with bacteriostatic water, hold at 2–8°C, use within 28 days, and avoid light exposure and repeated freeze-thaw cycles.
This product is intended strictly for in vitro and laboratory research use only. It is not approved for human consumption or therapeutic application, and no medical or clinical claims are made.
